A large national epidemiologic study was able to review a very large database of the diabetic male population through the use of managed care claims.

The study used this database to determine the prevalence of diabetes in men with and without ED. The prevalence of diabetes in men with ED was found to be much higher than the general population. Twenty percent of men suffering from ED were also found to have been diagnosed with diabetes; this is in comparison to only 7.5% in men without ED – to treat erectile dysfunction try cheap australia viagra online.

Given this finding that men with ED are twice as likely to have diabetes as those without ED, the diagnosis of ED may indeed serve as a useable marker for diabetic screening. A similarly large national study in 2005 evaluating men with ED found four specific comorbidities to be significantly prevalent among men carrying the diagnosis of ED. The authors even suggested that ED may be used as an observable marker for all four: hypertension, hyperlipidemia, depression, and diabetes Although treatment of ED is discussed later in the book, it is prudent to mention here that certain trials in the past decade have been specifically dedicated to the treatment of ED in diabetic males. A retrospective analysis of data from twelve placebo-controlled trials evaluated the efficacy and safety of tadalafil for the treatment of ED in diabetic males. They confirmed that diabetic men have more severe ED than controls at baseline. Interestingly, they also found that baseline erectile function in the diabetic males correlated inversely with baseline HbA(1)c levels. They concluded that although ED was found to be more severe in the diabetic population, response to tadalafil was only slightly lower than controls for the treatment of ED. Metabolic Syndrome An estimated 47 million people in the USA have metabolic syndrome.

Metabolic Syndrome is a combination of medical disorders thatincrease an individual’s risk for CAD and diabetes. Components of the syndrome include abdominal obesity, atherogenic dyslipidemia, hypertension, insulin resistance, prothrombotic states, and proinflammatory states. Correlation between metabolic syndrome and ED has been well established and mirrors the association of CAD or diabetes with the syndrome. Reported prevalence of ED in patients with metabolic syndrome falls between 26.7% and virtually 100%, and this prevalence increases as the number of components of the metabolic syndrome increases.

Of mention, hyperhomocysteinemia is an emerging risk factor for the development of ED in diabetic men. Further studies are needed to evaluate the exact mechanism by which this metabolite exerts its effect.